Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Individualizirano sistemsko zdravljenje pljučnega raka : realnost ali utopija?
Authors:ID Čufer, Tanja (Author)
Files:.pdf PDF - Presentation file, download (159,97 KB)
MD5: 3F0B4502FBAC399BFAC6E69442AB8B1C
PID: 20.500.12556/dirros/2c7fa5a9-5985-46ef-99c3-c59ed3172434
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Abstract:Pljučni rak je najpogostejši vzrok smrti zaradi raka pri moških in pri ženskah. Incidenca in umrljivost zaradi pljučnega raka pri ženskah narašča, medtem ko pri moških v razvitem svetu že stagnira. V Sloveniji na leto zboli že več kot 1000 bolnikov. Petletno preživetje se je v zadnjih 15 letih podaljšalo samo za 2,2 %. Napredek v zdravljenju je pričakovati od individualiziranega, vsakemu bolniku in njegovemu tumorju prilagojenega sistemskega zdravljenja. V prispevku so opisane možnosti individualiziranega zdravljenja pljučnega raka – bolnikovim lastnostim (starosti, zmogljivosti, spremljajočim obolenjem) prilagojenega zdravljenja in molekularnim značilkam bolnikovega tumorja prilagojenega citostatskega in tarčnega zdravljenja nedrobnoceličnega pljučnega raka. Podan je podroben pregled dosedanjih izsledkov učinkovitosti tarčnega zdravljenja s proti EGFR (receptor za epidermalni rastni dejavnik) in proti VEGF (žilni rastni dejavnik) usmerjenimi zdravili. Prikazane pa so tudi smeri razvoja tega zdravljenja. Pričakovati je, da bo individualizirano zdravljenje v bližnji prihodnosti bistveno izboljšalo učinkovitost sistemskega zdravljenja nedrobnoceličnega pljučnega raka. Zavedati pa se moramo, da je za učinkovito individualizirano sistemsko zdravljenje treba znati molekularne tarče dobro opredeliti, zanesljivo določiti, uporabo tarčnih zdravil pa prilagoditi posameznemu bolniku.
Publication status:Published
Publication version:Version of Record
Year of publishing:2010
Number of pages:str. 111-115, 168
Numbering:Letn. 14, št. 2
PID:20.500.12556/DiRROS-9099 New window
UDC:616-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-VI4BERT8
COBISS.SI-ID:28110553 New window
Copyright:by Authors
Note:BSDOCID156372;
Publication date in DiRROS:31.08.2018
Views:2332
Downloads:590
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Title:Individualized Systemic Treatment of Lung Cancer - A Real Fact or Utopia?
Abstract:Lung cancer is the leading cause of cancer-related death in men and women. Over the last decade, lung cancer incidence and mortality in developed countries increased in women, while the corresponding rates in men remained stable. Approximately 1000 new patients are diagnosed with lung cancer in Slovenia each year. During the last 15 years, the 5-year survival rates of patients with lung cancer increased by only 2.2%. Further progress is expected by introducing individualized, patient and tumor characteristics tailored systemic therapy strategies in the treatment of lung cancer. In this article, the current possibilities of individualized systemic therapies tailored to the patient (age, performance status, co-morbidities) as well as primary tumor characteristics are presented. A comprehensive overview of so far explored targeted therapies, aimed at the two most explored molecular targets in non-small cell lung cancer, i.e. EGFR (epidermal growth factor receptor) and VEGF (vascular epidermal growth factor), is presented. Future individualized treatment strategies and ongoing clinical research in this ever expanding field are outlined. It is expected that the individualized treatment approach will improve the effectiveness of systemic therapy of lung cancer in near future. However, one must be aware of the fact that there are some prerequisites for effective individualized therapy, i.e. molecular targets have to be defined very precisely, accurately determined in each individual tumor and targeted systemic therapy has to be carefully tailored to each individual patient.


Archive

niGradiv

Back